Aura Biosciences Stock

aurabiosciences.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $225.08MM

Aura Biosciences is a biotechnology company developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed.

Register To Buy and Sell Shares

For more details on financing and valuation for Aura Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Aura Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Aura Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Elisabet de los Pinos Ph.D
Co-Founder, Chief Executive Officer & Board Member
Denis O'Shaughnessy Ph.D
Head of Clinical Development
Richard Peters Ph.D
Advisor
Andrew Russell Ph.D
Director, Manufacturing
Stephen Monks Ph.D
Senior Vice President, Development
Alan Walts Ph.D
Executive Chairman
Julie Feder
Chief Financial Officer
Cadmus Rich MD
Chief Medical Officer
Michele Keough
Senior Vice President, R&D Operations

Board Members

Dale Pfost Ph.D
Advent Venture Partners
Elisabet de los Pinos Ph.D
Casper Breum
Lundbeckfonden
Henri Termeer
Javier García
Columbus Venture Partners
Rajesh Parekh Ph.D
Advent Life Sciences
Arthur Pappas
Chiesi Ventures
Giovanni Mariggi Ph.D
Medicxi
Joël Jean-Mairet Ph.D
Ysios Capital
Salvador Garcia-Atance Ph.D
Israel Ruiz
Alan Walts Ph.D
Mark Chin
Arix Bioscience

News Highlights

Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors
Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tum
Updated on: Feb 29, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.